AR085040A1 - INHIBICION DE LA IL-17 Y DEL IFN-g PARA EL TRATAMIENTO DE LAS INFLAMACIONES AUTOINMUNES - Google Patents

INHIBICION DE LA IL-17 Y DEL IFN-g PARA EL TRATAMIENTO DE LAS INFLAMACIONES AUTOINMUNES

Info

Publication number
AR085040A1
AR085040A1 ARP120100297A ARP120100297A AR085040A1 AR 085040 A1 AR085040 A1 AR 085040A1 AR P120100297 A ARP120100297 A AR P120100297A AR P120100297 A ARP120100297 A AR P120100297A AR 085040 A1 AR085040 A1 AR 085040A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
co2r
heterocyclyl
heteroaryl
Prior art date
Application number
ARP120100297A
Other languages
English (en)
Inventor
Leban Johann Dr
Tasler Stefan Dr
Baumgartner Roland Dr
Saeb Wael Dr
Chevrier Carine Dr
Original Assignee
4Sc Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Discovery Gmbh filed Critical 4Sc Discovery Gmbh
Publication of AR085040A1 publication Critical patent/AR085040A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso como agentes antiinflamatorios e inmunomoduladores.Reivindicación 1: Un compuesto caracterizado porque es de la fórmula general (1) y sales aceptables farmacéuticamente o solvatos del mismo, donde R1 es arilo, heteroarilo, cicloalquilo, heterociclilo o alquilo, que puede estar sustituido con uno o más sustituyentes R’; Ar es arilo, cicloalquilo, heterociclilo o heteroarilo, que puede estar sustituido con uno o más sustituyentes R’; Z es H, halógeno, -CR’’O, -N(R’’)2, -CN, -C(S)R’’, -N=C(R’)2, -CO2R’’, -NR’CO2R’’, -CONHR’’, -CON(R”)2, -COSR’’, -CSNHR’’, -CSN(R”)2, -SO2-alquilo, -SO2-haloalquilo, -SO2NHR’’, -SO2(NR”)2, amino o -SO2R’’; Y es H, halógeno, haloalquilo, alquilo o un alquiléster, que puede estar sustituido con uno o más sustituyentes R’; R’ representa en forma independiente H, -CO2R’’, -CONHR’’, -CR”O, -SO2N(R”)2, -SO2NHR’’, -NR”-CO-haloalquilo, -NO2, -NR”-SO2-haloalquilo, -NR”-SO2-alquilo, -SO2- alquilo, -NR’’-CO-alquilo, -CN, alquilo, cicloalquilo, aminoalquilo, alquilamino, alcoxi, -OH, -SH, alquiltio, hidroxialquilo, hidroxialquilamino, halógeno, haloalquilo, haloalcoxi, amino, heterociclilo, arilo, haloarilo, haloarilalquilo, arilalquilo o heteroarilo; R” representa en forma independiente H, haloalquilo, hidroxialquilo, amino, alcoxi, -N=C(R’)2, -NR’-CO-R’, -CR’O, -CO2R’, alquilo, cicloalquilo, arilo, haloarilo, haloarilalquilo, heteroarilo, heterociclilo, arilalquilo o aminoalquilo, que están opcionalmente sustituidos con uno o más sustituyentes R’.
ARP120100297A 2011-01-28 2012-01-30 INHIBICION DE LA IL-17 Y DEL IFN-g PARA EL TRATAMIENTO DE LAS INFLAMACIONES AUTOINMUNES AR085040A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437061P 2011-01-28 2011-01-28
EP11152515 2011-01-28

Publications (1)

Publication Number Publication Date
AR085040A1 true AR085040A1 (es) 2013-08-07

Family

ID=46577835

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100297A AR085040A1 (es) 2011-01-28 2012-01-30 INHIBICION DE LA IL-17 Y DEL IFN-g PARA EL TRATAMIENTO DE LAS INFLAMACIONES AUTOINMUNES

Country Status (23)

Country Link
US (1) US8592456B2 (es)
EP (1) EP2668182B1 (es)
JP (1) JP5969505B2 (es)
KR (1) KR101875248B1 (es)
CN (1) CN103476771B (es)
AR (1) AR085040A1 (es)
AU (1) AU2012210489B2 (es)
BR (1) BR112013019011B1 (es)
CA (1) CA2825684C (es)
DK (1) DK2668182T3 (es)
EA (1) EA027351B1 (es)
ES (1) ES2664507T3 (es)
IL (1) IL227626A0 (es)
MX (1) MX353762B (es)
MY (1) MY162397A (es)
PL (1) PL2668182T3 (es)
PT (1) PT2668182T (es)
RU (1) RU2013139663A (es)
SG (1) SG192176A1 (es)
TW (1) TWI520955B (es)
UA (1) UA113160C2 (es)
UY (1) UY33884A (es)
WO (1) WO2012101261A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013139662A (ru) * 2011-01-28 2015-03-10 4-Эс-Си Дискавери Гмбх Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления
EP2738170B1 (en) * 2011-07-29 2017-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
UA117913C2 (uk) 2012-05-31 2018-10-25 Фінекс Фармас'Ютікалс Аг КАРБОКСАМІД- АБО СУЛЬФОНАМІДЗАМІЩЕНІ ТІАЗОЛИ ТА СПОРІДНЕНІ ПОХІДНІ ЯК МОДУЛЯТОРИ ОРФАНОВОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN104978732A (zh) * 2014-04-11 2015-10-14 中国船舶工业系统工程研究院 一种摄像机参数标定板
CA3198322A1 (en) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека
CN111433202A (zh) 2017-09-06 2020-07-17 埃慕尼克股份公司 作为IL-17和IFN-γ抑制剂用于治疗自体免疫疾病和慢性炎症的1-(4-(异*唑-5-基)-1H-吡唑-1-基)-2-甲基丙-2-醇衍生物和相关化合物
WO2019223718A1 (zh) * 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341442B (zh) * 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341519A (zh) * 2019-08-09 2021-02-09 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027729A1 (zh) * 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341435B (zh) * 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
WO2023281097A1 (en) 2021-07-09 2023-01-12 Immunic Ag Methods for treating cancer
WO2023198873A1 (en) 2022-04-14 2023-10-19 Immunic Ag Deuterated rorgamma/rorgammat inverse agonists
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172985T1 (de) * 1993-02-09 1998-11-15 Bayer Ag Sulfonamidaminomethylenderivate als immunsuppressiva
JP3237608B2 (ja) * 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
AU733091B2 (en) * 1997-04-21 2001-05-03 Dainippon Sumitomo Pharma Co., Ltd. Isoxazole derivatives
US20060089398A1 (en) * 2003-03-19 2006-04-27 Gang Liu Isoxazole carboxamide derivatives as ghrelin receptor modulators
RS50796B (sr) * 2004-03-09 2010-08-31 Boehringer Ingelheim Pharmaceuticals Inc. 3-[4-heterociklil-1,2,3-triazol-1-il]-n-aril-benzamidi kao inhibitori produkcije citokina za lečenje hroničnih inflamatornih oboljenja
TW200826936A (en) * 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2012504604A (ja) * 2008-10-01 2012-02-23 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用のための化合物
AR076984A1 (es) * 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
RU2013139662A (ru) * 2011-01-28 2015-03-10 4-Эс-Си Дискавери Гмбх Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления

Also Published As

Publication number Publication date
EA027351B1 (ru) 2017-07-31
EP2668182B1 (en) 2017-11-01
NZ613592A (en) 2015-03-27
WO2012101261A1 (en) 2012-08-02
MX353762B (es) 2018-01-26
JP5969505B2 (ja) 2016-08-17
AU2012210489B2 (en) 2017-01-12
DK2668182T3 (da) 2018-01-29
CN103476771A (zh) 2013-12-25
JP2014504608A (ja) 2014-02-24
TW201309682A (zh) 2013-03-01
PL2668182T3 (pl) 2018-11-30
KR101875248B1 (ko) 2018-08-02
MX2013008718A (es) 2014-02-17
ES2664507T3 (es) 2018-04-19
CA2825684C (en) 2021-11-23
CN103476771B (zh) 2015-12-23
RU2013139663A (ru) 2015-03-10
BR112013019011B1 (pt) 2021-10-13
UY33884A (es) 2012-08-31
BR112013019011A2 (pt) 2017-07-11
US20120196861A1 (en) 2012-08-02
EA201300862A1 (ru) 2014-04-30
IL227626A0 (en) 2013-09-30
PT2668182T (pt) 2018-01-31
KR20140041440A (ko) 2014-04-04
MY162397A (en) 2017-06-15
CA2825684A1 (en) 2012-08-02
AU2012210489A1 (en) 2013-08-15
UA113160C2 (xx) 2016-12-26
EP2668182A1 (en) 2013-12-04
US8592456B2 (en) 2013-11-26
TWI520955B (zh) 2016-02-11
SG192176A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
AR085040A1 (es) INHIBICION DE LA IL-17 Y DEL IFN-g PARA EL TRATAMIENTO DE LAS INFLAMACIONES AUTOINMUNES
AR085038A1 (es) COMPUESTOS UTILES EN LA INHIBICION DE LA IL-17 Y DEL IFN-g PARA EL TRATAMIENTO DE LAS INFLAMACIONES AUTOINMUNES
CR20140084A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
SMT201500191B (it) Derivati di benzopirazina sostituiti come inibitori delle chinasi fgfr per il trattamento di malattie tumorali
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
CY1122920T1 (el) ΑΛΑΤΑ ΠΑΡΑΓΩΓΩΝ 2-ΑΜΙΝΟ-1-ΥΔΡΟΞΥΑΙΘΥΛ-8-ΥΔΡΟΞΥΚΙΝΟΛΙΝ-2(1Η)-ΟΝΗΣ ΠΟΥ ΕΧΟΥΝ ΔΡΑΣΕΙΣ ΤΟΣΟ ΑΝΤΑΓΩΝΙΣΤΗ ΜΟΥΣΚΑΡΙΝΙΚΩΝ ΥΠΟΔΟΧΕΩΝ ΟΣΟ ΚΑΙ ΑΓΩΝΙΣΤΗ β2 ΑΔΡΕΝΕΡΓΙΚΩΝ ΥΠΟΔΟΧΕΩΝ
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
AR067646A1 (es) Ariloxazoles sustituidos y su uso
MX2018003649A (es) Metodos e intermedios para la preparacion de derivados de acido biliar.
CR20140464A (es) Compuestos de heterociclilo
AR077765A1 (es) Inhibidores de los virus flaviviridae
CO2019005824A2 (es) Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v
CR20160514A (es) Derivados de indol para uso en medicina
CR20120397A (es) Inhibidores del virus de la hepatitis c
UY36152A (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo
EA201590674A1 (ru) Производные 5-фенокси-3h-пиримидин-4-она и их применение в качестве ингибиторов обратной транскрипазы вич
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
EA201500875A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
CR20140294A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CY1119425T1 (el) Ενωσεις φαινοξυαιθυλο πιπεριδινης
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR073932A1 (es) Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak
AR084637A1 (es) Compuestos heterociclicos apropiados para el tratamiento de la dislipidemia

Legal Events

Date Code Title Description
FG Grant, registration